drug · small molecule

MEKINIST

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 6

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 3 investigational indications.

targets

Dual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1

all catalysts(0)

nothing on the calendar yet

Trials studying MEKINIST

—Special Drug Use-results Surveillance of Tafinlar/Mekinistrecruitingn=110
phase2Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancercompletedn=27

News(0)

no news has mentioned this drug yet

brand

MEKINIST

trade names

Mekinist, Spexotras

generic

TRAMETINIB DIMETHYL SULFOXIDE

MOA

12.1 Mechanism of Action Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. Trametinib inhibits cell growth of various BRAF V600 mutation-positive tumors in vitro and in vivo. Trametinib and dabrafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of trametinib and dabrafenib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation-positive tumor xenografts compared with either drug alone. In the setting of BRAF-mutant colorectal cancer, induction of EGFR-mediated MAPK pathway re-activation has been identified as a mechanism of intrinsic resistance to BRAF inhibitors [see Indications and Usage (1.7)] .

indication

1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) 1.1 BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma MEKINIST ® is indicate

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 12m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

MEKINIST

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 6

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 3 investigational indications.

targets

Dual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1

all catalysts(0)

nothing on the calendar yet

Trials studying MEKINIST

—Special Drug Use-results Surveillance of Tafinlar/Mekinistrecruitingn=110
phase2Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancercompletedn=27

News(0)

no news has mentioned this drug yet

brand

MEKINIST

trade names

Mekinist, Spexotras

generic

TRAMETINIB DIMETHYL SULFOXIDE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 12m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

MEKINIST

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying MEKINIST

News(0)

Report a data issue

comments(0)

MEKINIST

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying MEKINIST

News(0)

Report a data issue

comments(0)